Histogen Inc. (HSTOQ)

Market Cap	106.79K
Revenue (ttm)	19.00K
Net Income (ttm)	-12.38M
Shares Out	4.27M
EPS (ttm)	-2.90
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	376
Open	0.0250
Previous Close	0.0277
Day's Range	0.0250 - 0.0250
52-Week Range	n/a
Beta	1.12
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 7, 2025

About Histogen

Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function. The company’s product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of vari...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Employees: 7
• Stock Exchange: OTCMKTS
• Ticker Symbol: HSTOQ

Financial Performance

In 2022, Histogen's revenue was $3.77 million, an increase of 265.21% compared to the previous year's $1.03 million. Losses were -$11.11 million, -25.69% less than in 2021.